
|Articles|August 31, 2011
Novel Cancer-Targeting Virus Therapy Shows Efficacy in Early-Stage Trial
Author(s)Anna Azvolinsky
Scientists at Jennerex, Inc. in San Francisco, and collaborators from University of Pennsylvania and the University of Ottawa in Canada have just engineered a poxvirus, JX-594, to selectively replicate in tumor cells that have an activated EGFR/ Ras pathway, but not in normal tissue.
Advertisement
Array
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Prophylaxis and Practical Implementation of the COPERNICUS Approach
2
Pirtobrutinib Monotherapy Earns Canadian Approval in Lymphoma/Leukemia Populations
3
Palbociclib Maintenance Extends PFS in HR+/HER2+ Advanced Breast Cancer
4
FDA Receives NDA for Lirafugratinib in 2L FGR2-Mutated Cholangiocarcinoma
5


































